These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 5022155)

  • 1. [Study, outline and formulation of pharmaceutical preparations with delayed action].
    Arancibia A
    Farmaco Prat; 1972 Apr; 27(4):181-204. PubMed ID: 5022155
    [No Abstract]   [Full Text] [Related]  

  • 2. [Absorption of the drug-contents of enteric-coated tablets].
    Tikkanen R
    Nord Med; 1967 Nov; 78(47):1564-7. PubMed ID: 6075282
    [No Abstract]   [Full Text] [Related]  

  • 3. [Effect of formulation of enterosoluable preparations on the physiologic availability of the active principle. 1: Effect on the rate of liberation of acetylsalicylic acid from enteric tablets on absorption characteristics in vivo].
    Delporte JP; Jaminet F
    J Pharm Belg; 1975; 30(2):99-113. PubMed ID: 1206458
    [No Abstract]   [Full Text] [Related]  

  • 4. [Influence of formulation of enterosoluble preparations on the physiologic disposition of the active principle. Part III. Establishment of quantitative correlations between the rate of dissolution in vitro of the active principle and its absorption characteristics].
    Delporte JP
    J Pharm Belg; 1976; 31(2):150-68. PubMed ID: 950582
    [No Abstract]   [Full Text] [Related]  

  • 5. Therapeutic inequivalence of pharmaceutical alternates.
    Levy RA
    Am Pharm; 1985 Apr; NS25(4):28-39. PubMed ID: 3893084
    [No Abstract]   [Full Text] [Related]  

  • 6. Drug delivery systems 5B. Oral drug delivery.
    Ranade VV
    J Clin Pharmacol; 1991 Feb; 31(2):98-115. PubMed ID: 2010566
    [No Abstract]   [Full Text] [Related]  

  • 7. Formulations and dosages of oral drugs.
    Calesnick B
    Am Fam Physician; 1978 Sep; 18(3):160-2. PubMed ID: 685796
    [No Abstract]   [Full Text] [Related]  

  • 8. Preparation of sustained release hydrophilic matrices by melt granulation in a high-shear mixer.
    Ochoa L; Igartua M; Hernández RM; Gascón AR; Pedraz JL
    J Pharm Pharm Sci; 2005 Jun; 8(2):132-40. PubMed ID: 16124924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Importance of pharmaceutical formulation for drug absorption.
    Sjögren J
    Acta Pharmacol Toxicol (Copenh); 1971; 29 Suppl 3():68-80. PubMed ID: 5316412
    [No Abstract]   [Full Text] [Related]  

  • 10. In vivo pharmacodynamic evaluation of oral dosage forms by whole body liquid scintillometry.
    Hecht G; Christian JE; Banker GS
    J Pharm Sci; 1966 Jul; 55(7):678-84. PubMed ID: 5967745
    [No Abstract]   [Full Text] [Related]  

  • 11. Oral modified-release formulations in motion: the relationship between gastrointestinal transit and drug absorption.
    Varum FJ; Merchant HA; Basit AW
    Int J Pharm; 2010 Aug; 395(1-2):26-36. PubMed ID: 20546855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and evaluation of 1- and 3-layer matrices of verapamil hydrochloride for sustaining its release.
    Siahi MR; Barzegar-Jalali M; Monajjemzadeh F; Ghaffari F; Azarmi S
    AAPS PharmSciTech; 2005 Dec; 6(4):E626-32. PubMed ID: 16408864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the accuracy of different types of dissolution rate methods.
    Bolhuis GK; Lerk CF; Zuurman K
    Pharm Weekbl; 1973 Jan; 108(3):49-53. PubMed ID: 4699088
    [No Abstract]   [Full Text] [Related]  

  • 14. The relation of product formulation to absorption of oral theophylline.
    Weinberger M; Hendeles L; Bighley L
    N Engl J Med; 1978 Oct; 299(16):852-7. PubMed ID: 692577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug formulation and biologic availability.
    Poole JW
    Semin Drug Treat; 1971 Sep; 1(2):148-76. PubMed ID: 5153883
    [No Abstract]   [Full Text] [Related]  

  • 16. Influence of formulation and process parameters on pellet production by powder layering technique.
    Nastruzzi C; Cortesi R; Esposito E; Genovesi A; Spadoni A; Vecchio C; Menegatti E
    AAPS PharmSciTech; 2000 May; 1(2):E9. PubMed ID: 14727842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral controlled release preparations.
    García CR; Siqueiros A; Benet LZ
    Pharm Acta Helv; 1978; 53(3-4):99-109. PubMed ID: 360228
    [No Abstract]   [Full Text] [Related]  

  • 18. Preliminary evaluation of the in vitro release and in vivo absorption in rabbits of the modified-release dosage forms.
    Petrovic AA; Petricevic SM; Ristic SM; Ibric SR; Simic SS; Djuric ZR; Popovic RB
    Drug Dev Ind Pharm; 2013 Jun; 39(6):889-900. PubMed ID: 22905673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of processing parameters and formulation factors on the drug release from tablets powder-coated with Eudragit L 100-55.
    Sauer D; Zheng W; Coots LB; McGinity JW
    Eur J Pharm Biopharm; 2007 Sep; 67(2):464-75. PubMed ID: 17451929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained delivery of intact drug to the colon: mesalamine formulation and temporal gastrointestinal transit analysis.
    Chuong MC; Christensen JM; Ayres JW
    Pharm Dev Technol; 2009; 14(1):116-25. PubMed ID: 18821272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.